Skip to main content

Table 1 Clinical characteristics of patients with SFTS-associated encephalitis/encephalopathy

From: Clinical feature of severe fever with thrombocytopenia syndrome (SFTS)-associated encephalitis/encephalopathy: a retrospective study

 

All SFTS patients

(N = 109)

Encephalitis/encephalopathy patients

(N = 30)

Non-encephalitis/encephalopathy patients

(N = 79)

P

Demographic characteristics

Age, years

60.69 ± 12.53

64.07 ± 10.21

59.34 ± 13.16

0.086

Sex, male (%)

45 (41.3)

18 (60)

27(34.2)

0.028

Days prior to admission (days)

6.95 ± 2.42

6.73 ± 2.30

7.04 ± 2.57

0.559

Underlying diseases, n (%)

Hypertension

24 (22.2)

9 (30)

15 (19)

0.163

Diabetes

12 (11)

6 (20)

6 (7.6)

0.071

Clinical manifestation, n (%)

Fever

109 (100)

30 (100)

79 (100)

–

Headache

44(40.4)

30 (100)

14 (17.7)

< 0.001

Cough

36 (33.3)

15 (50)

21 (26.6)

0.014

Wheezing

33 (30.3)

16 (53.3)

17 (21.5)

0.002

Dyspnoea

10 (9.23)

6 (20)

4 (5.1)

0.013

Vomiting/diarrhoea

10 (9.2)

1 (0.9)

9 (8.3)

0.002

Laboratory findings at admission

Leukocytes (*109/L)

(normal range, 4–10)

2.85 (1.70–4.63)

2.80 (1.78–4.55)

3 (1.63–4.68)

0.763

Percentage of neutrophils (%) (normal range, 50–70)

55.10 (39.58–72.60)

58.8 (48.9-74.78)

52.15 (38.03–72.60)

0.167

Percentage of lymphocytes (%)

(normal range, 20–40)

34.05 (20.70-45.35)

30.1 (21.35–41.83)

35.8 (20.7-47.23)

0.309

Haemoglobin (g/L)

(normal range, 110–160)

127.50 (115–142)

130.5 (118–143)

126.5(114.75-141.25)

0.433

Platelets (*109/L)

(normal range, 100–300)

47.50 (32–66.25)

42.5 (29.5-64.25)

49 (33.25–69.75)

0.208

PCT (µg/L)

(normal range,0-0.5)

0.30 (10.12–0.86)

0.58 (0.24–3.17)

0.22 (0.1–0.73)

0.005

CRP (mg/L)

(normal range,0–8)

6.8 (3.15–15.2)

11.55 (4.15–38.75)

5.4 (3–12)

0.016

ALT (U/L)

(normal range, 0–40)

73.2 (51.05–137.2)

83 (60.58-168.43)

71.1 (148.8-120.7)

0.167

AST (U/L)

(normal range, 0–40)

159.05 (89.55–264.40)

231.90 (129.93-547.73)

122.3 (88.28–234.75)

0.008

LDH(U/L)

(normal range, 109–245)

1679 (1326–2595)

1683 (1245–2788)

1430 (1125–2846)

0.623

CK(U/L)

(normal range, 25–200)

1027 (506–1528)

1110 (392–2020)

993 (465–1720)

0.912

Amylase (U/L)

(normal range, 25–115)

119 (61–195)

185 (87–266.5)

105 (47–163)

0.003

Comorbidity, n (%)

Respiratory failure

10 (9.2)

6 (20)

4 (5.1)

0.013

Vasopressors use

27 (24.8)

13 (43.3)

14 (17.7)

0.001

Acute kidney injury

17 (15.6)

8 (26.7)

9 (11.4)

0.074

Bacteraemia

12 (11)

8 (26.7)

4 (5.1)

< 0.001

Probable or proven-IPA

38 (34.9)

17 (56.7)

21 (26.6)

0.004

Treatment, n (%)

Immunoglobulin

35 (32.1)

14 (46.7)

21 (26.6)

< 0.001

Ribavirin

102 (93.6)

30 (100)

72 (91.1)

0.097

Methylprednisolone

22 (20.2)

10 (33.3)

12 (15.2)

< 0.001

Outcome

ICU transfer, n (%)

16 (14.7)

11 (36.7)

5 (6.3)

< 0.001

Length of hospital stay (days)

9 (6.5–13)

9 (6–11.25)

10 (7–13)

0.272

In-hospital mortality, n (%)

23 (21.1)

13 (43.3)

10 (12.7)

< 0.001

  1. PCT procalcitonin, CRP C-reactive protein, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactic dehydrogenase, CK creatine kinase, IPA invasive pulmonary aspergillosis